Chemotherapy Clinical Trial
— DICHIMIOOfficial title:
Is the Distance of Patients From Rouen University Hospital Influencing the Time Between Colectomy and First Chemotherapy Cure for Colon Cancer?
Verified date | October 2018 |
Source | University Hospital, Rouen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This project has for objective to demonstrate that the increase of the distance "Patient home - center of treatment" may be associated with significant, other noticeable, noted events. This distance may also be available in the Rouen University Hospital. The study of the association in this distance and the delay in initiating chemotherapy after surgery in patients treated at the CHU correspond to a pilot study prior to the completion of the analysis at the regional scale.
Status | Recruiting |
Enrollment | 140 |
Est. completion date | December 23, 2018 |
Est. primary completion date | January 23, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients who had colectomy for colon cancer and at least one chemotherapy treatment at CHU Rouen, between 2009 and the first half of 2015. Exclusion Criteria: - Patients who died in hospital before receiving a chemotherapy treatment - Patients with a CIM code of metastasis during the stay of the colectomy or the first chemotherapy treatment - Patients who received a chemotherapy treatment before colectomy - Patients who have undergone several colectomies. |
Country | Name | City | State |
---|---|---|---|
France | Rouen University Hospital | Rouen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Rouen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | distance "home of patients - treatment center" | Analyze the influence of distance "home of patients - treatment center" on the compliance of the time between colectomy and initiation of CTa | At the inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03652727 -
FX vs. ECG Guidance for PICC Insertion
|
N/A | |
Not yet recruiting |
NCT05856656 -
Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
Recruiting |
NCT00797238 -
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC
|
N/A | |
Not yet recruiting |
NCT05927857 -
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
|
Phase 1/Phase 2 | |
Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT04466332 -
Comparison of Two ECG Guided PICC Insertion Techniques
|
N/A | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03701607 -
Effect of Chemotherapy on PD-L1 in NSCLC
|
||
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Recruiting |
NCT06208436 -
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
|
||
Recruiting |
NCT05306301 -
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
|
Phase 2 | |
Active, not recruiting |
NCT02304640 -
Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
|
||
Completed |
NCT02298972 -
Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer
|
N/A | |
Terminated |
NCT01249001 -
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
|
Phase 2 | |
Recruiting |
NCT03089892 -
A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy
|
N/A | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Recruiting |
NCT04472403 -
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
|
||
Terminated |
NCT02982694 -
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
|
Phase 2 |